Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment

Pharmacogenomics

Volumn 11, Issue 7, 2010, Pages 927-941

  Grover, Sandeep ^a   Gourie Devi, Mandaville ^b   Baghel, Ruchi ^a   Sharma, Sangeeta ^b   Bala, Kiran ^b   Gupta, Meena ^b   Narayanasamy, Krishnamoorthy ^c   Varma, Binuja ^c   Gupta, Meenal ^a   Kaur, Kavita ^a   Talwar, Puneet ^a   Kaur, Harpreet ^a   Giddaluru, Sudheer ^a   Sharma, Abhay ^a   Brahmachari, Samir K ^a   Consortium, Indian Genome Variation ^a   Kukreti, Ritushree ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

^b INSTITUTE OF HUMAN BEHAVIOUR AND ALLIED SCIENCES   (India)

^c The Centre for Genomic Application TCGA   (India)

Author keywords

allele frequency; antiepileptic drug; drug response; genetic variant; metabolizer; patients with epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 2C19; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 1; MULTIDRUG RESISTANCE PROTEIN 1; PHENOBARBITAL; PHENYTOIN; SODIUM CHANNEL NAV1.1; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG CHOICE; DRUG RESPONSE; EPILEPSY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIA; PERSONALIZED MEDICINE; PHARMACOGENETICS; SIMPLE PARTIAL SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM; TONIC CLONIC SEIZURE;

EID: 77954367293     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.62     Document Type: Article

References (82)

1. Gourie-Devi M, Gururaj G, Satishchandra P, Subbakrishna DK: Prevalence of neurological disorders in Bangalore, India: a community-based study with a comparison between urban and rural areas. Neuro epidemiology 23, 261-268 (2004).
2. Radhakrishnan K: Challenges in the management of epilepsy in resource-poor countries. Nat. Rev. Neurol. 5, 323-330 (2009).
3. Marson AG, Kadir ZA, Hutton JL, Chadwick DW: The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38, 859-880 (1997).
4. Majumder PP: People of India: biological diversity and affnities. Evol. Anthrop. 6, 100-110 (1998)
5. The Indian Genome Variation database (IGVdb): a project overview. Hum. Genet. 118, 1-11 (2005).
6. Indian Genome Variation Consortium: Genetic landscape of the people of India: a canvas for disease gene exploration. J. Genet. 87, 3-20 (2008).
7. Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R: Allele and genotype frequency of CYP2C19 in a Tamilian population. Br. J. Clin. Pharmacol. 56, 331-333 (2003). (Pubitemid 37059662)
8. Lakhan R, Misra UK, Kalita J et al.: No association of ABCB1 polymorphisms with drug-refractory epilepsy in a North Indian population. Epilepsy Behav. 14, 78-82 (2009).
9. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
10. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P: Association mapping in structured populations. Am. J. Hum. Genet. 67, 170-181 (2000).
11. Pearce RE, Vakkalagadda GR, Leeder JS: Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites. Drug Metab. Dispos. 30, 1170-1179 (2002).
12. Sachse C, Brockmoller J, Bauer S, Roots I: Functional signifcance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445-449 (1999).
13. Kerr BM, Thummel KE, Wurden CJ et al.: Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 47, 1969-1979 (1994).
14. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug palitaxel and arachidonic acid. Pharmacogenetics 11, 597-607 (2001).
15. Ufer M, Mosyagin I, Muhle H et al.: Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics 19, 353-362 (2009).
16. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 175, 1112-1118 (1991).
17. Szoeke CE, Newton M, Wood JM et al.: Update on pharmacogenetics in epilepsy: a brief review. Lancet Neurol. 5, 189-196 (2006).
18. van der Weide J, Steijns LS, van Weelden MJ, de Haan K: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11, 287-291 (2001).
19. Goto S, Seo T, Murata T et al.: Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther. Drug Monit. 29, 118-121 (2007).
20. Lee SY, Lee ST, Kim JW: Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J. Biochem. Mol. Biol. 40, 448-452 (2007).
21. Tate SK, Singh R, Hung CC et al.: A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16, 721-726 (2006).
22. Mamiya K, Ieiri I, Shimamoto J et al.: The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39, 1317-1323 (1998).
23. Taguchi M, Hongou K, Yagi S et al.: Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab. Pharmacokinet. 20, 107-112 (2005).
24. Soga Y, Nishimura F, Ohtsuka Y et al.: CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci. 74, 827-834 (2004).
25. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics 15, 779-786 (2005).
26. Simon C, Stieger B, Kullak-Ublick GA et al.: Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol. Scand. 115, 232-242 (2007).
27. Argikar UA, Cloyd JC, Birnbaum AK et al.: Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Res. 71, 54-63 (2006).
28. Yasumori T, Chen LS, Li QH et al.: Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem. Pharmacol. 57, 1297-1303 (1999).
29. Yukawa E, Mamiya K: Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J. Clin. Pharm. Ther. 31, 275-282 (2006).
30. Odani A, Hashimoto Y, Otsuki Y et al.: Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 62, 287-292 (1997).
31. Mamiya K, Hadama A, Yukawa E et al.: CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur. J. Clin. Pharmacol. 55, 821-825 (2000).
32. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T: A major infuence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 26, 530-534 (2004).
33. Seo T, Nagata R, Ishitsu T et al.: Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics 9, 527-537 (2008).
34. Pelkonen O, Myllynen P, Taavitsainen P et al.: Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31, 321-343 (2001). (Pubitemid 32679311)
35. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR: Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42, 299-305 (2003).
36. Murayama N, Nakamura T, Saeki M et al.: CYP3A4 gene polymorphisms infuence testosterone 6ß-hydroxylation. Drug Metab. Pharmacokinet. 17, 150-156 (2002).
37. Tybring G, von Bahr C, Bertilsson L, Collste H, Glaumann H, Solbrand M: Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metab. Dispos. 9, 561-564 (1981).
38. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ: Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet. 3, 421-428 (1994).
39. Maekawa K, Itoda M, Hanioka N et al.: Non-synonymous single nucleotide alterations in the microsomal epoxide hydrolase gene and their functional effects. Xenobiotica 33, 277-287 (2003).
40. Nakajima Y, Saito Y, Shiseki K et al.: Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur. J. Clin. Pharmacol. 61, 25-34 (2005).
41. Nakajima M, Sakata N, Ohashi N, Kume T, Yokoi T: Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4́-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Drug Metab. Dispos. 30, 1250-1256 (2002).
42. Yamamoto K, Sato H, Fujiyama Y, Doida Y, Bamba T: Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim. Biophys. Acta 1406, 267-273 (1998).
43. Sai K, Saeki M, Saito Y et al.: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501-515 (2004).
44. Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7 J. Pharmacol. Exp. Ther. 311, 1131-1137 (2004).
45. Argikar UA, Remmel RP: Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos. 37, 229-236 (2009).
46. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP: Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastro enterology 132, 272-281 (2007).
47. Sawyer MB, Innocenti F, Das S et al.: A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73, 566-574 (2003).
48. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55, 1364-1375 (2008).
49. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE: Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J. Pharmacol. Exp. Ther. 307, 262-267 (2003).
50. Potschka H, Fedrowitz M, Loscher W: P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12, 3557-3560 (2001).
51. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3 473-3 478 (2000).
52. Kerb R, Aynacioglu AS, Brockmoller J et al.: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1, 204-210 (2001).
53. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH: Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6, 411-417 (2005).
54. Kwan P, Wong V, Ng PW et al.: Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics 10, 723-732 (2009).
55. Zimprich F, Sunder-Plassmann R, Stogmann E et al.: Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy Neurology 63, 1087-1089 (2004).
56. Szoeke C, Sills GJ, Kwan P et al.: Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from International Pharmacogenetic Cohorts. Epilepsia 50(7), 1689-1696 (2009).
57. Siddiqui A, Kerb R, Weale ME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003).
58. Ozgon GO, Bebek N, Gul G, Cine N: Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur. Neurol. 59, 67-70 (2008).
59. Chen L, Liu CQ, Hu Y, Xiao ZT, Chen Y, Liao JX: Association of a polymorphism in MDR1 C3435T with response to antiepileptic drug treatment in ethic Han Chinese children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 9, 11-14 (2007).
60. Kwan P, Baum L, Wong V et al.: Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 11, 112-117 (2007).
61. Sills GJ, Mohanraj R, Butler E et al.: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46, 643-647 (2005).
62. Kim DW, Kim M, Lee SK, Kang R, Lee SY Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15, 344-347 (2006).
63. Dericioglu N, Babaoglu MO, Yasar U, Bal IB, Bozkurt A, Saygi S: Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene. Epilepsy Res. 80, 42-46 (2008).
64. Tan NC, Heron SE, Scheffer IE et al.: Failure to confrm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy Neurology 63, 1090-1092 (2004).
65. Mosyagin I, Runge U, Schroeder HW et al.: Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 49, 1555-1561 (2008).
66. Basic S, Hajnsek S, Bozina N et al.: The infuence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 17, 524-530 (2008).
67. Seo T, Ishitsu T, Ueda N et al.: ABCB1 polymorphisms infuence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7, 551-561 (2006).
68. Kim DW, Lee SK, Chu K et al.: Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy Epilepsy Res. 84, 86-90 (2009).
69. Ebid AH, Ahmed MM, Mohammed SA: Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther. Drug Monit. 29, 305-312 (2007).
70. Shahwan A, Murphy K, Doherty C et al.: The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 73, 192-198 (2007).
71. Schwarz JR, Grigat G: Phenytoin and carbamazepine: potential-and frequency-dependent block of Na currents in mammalian myelinated nerve fbers. Epilepsia 30, 286-294 (1989).
72. Tate SK, Depondt C, Sisodiya SM et al.: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102, 5507-5512 (2005).
73. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K: Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol. 66, 304-307 (2008).
74. Zimprich F, Stogmann E, Bonelli S et al.: A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy Epilepsia 49, 1108-1109 (2008).
75. Schlachter K, Gruber-Sedlmayr U, Stogmann E et al.: A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures. Neurology 72, 974-978 (2009).
76. Kwan P, Poon WS, Ng HK et al.: Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet. Genomics 18, 989-998 (2008).
77. +-channel b 1 subunit gene SCN1B. Nat. Genet. 19, 366-370 (1998).
78. Lucas PT, Meadows LS, Nicholls J, Ragsdale DS: An epilepsy mutation in the b 1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res. 64, 77-84 (2005).
79. Sun H, Zhang Y, Liang J et al.: SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus. J. Hum. Genet. 53, 769-774 (2008).
80. Haider MZ, Habeeb Y, Al-Nakkas E et al.: Lack of an association between candidate gene loci and idiopathic generalized epilepsy in Kuwaiti Arab children. J. Biomed. Sci. 12, 815-818 (2005).
81. + channel a II subunit gene Na(v) 1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc. Natl Acad. Sci. USA 98, 6384-6389 (2001).
82. Herlenius E, Heron SE, Grinton BE et al.: SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum. Epilepsia 48, 1138-1142 (2007).